Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
Date:7/13/2009

ATLANTA, July 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY),an implantable biological medical device and cardiovascular tissue processing company,announced today that 2009 second quarter financial results will be released on Thursday, July 30, 2009. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available July 30 through August 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 327576.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife Web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve((R)) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft((R)) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves. The Company's BioGlue((R)) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com.

    Media Contacts:

    D. Ashley Lee                               Katie Brazel
    Executive Vice President, Chief Financial   Fleishman Hillard
    Officer and Chief Operating Officer         Phone: 404-739-0150
    Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
2. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
3. William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
4. Cryolife Victim Responds to Untrue Assertions of Cryolife
5. CryoLife Announces Additions to Management Team
6. Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
7. Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System
8. ONRAD Announces its "Name Our Ant" Competition
9. U.S. Non-Profit Announces Opening of Life-Saving Dialysis Facility in Philippines
10. Pederson Immigration Law Group Announces 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series
11. CBCA Administrators, Inc. Announces Partnership with Bravo Wellness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
(Date:1/20/2017)... ... ... and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is ... a devoted woman of faith. , “Becoming a parent changes you. In my case, ... for years, but actually doing it might have been a while in coming if it ...
(Date:1/20/2017)... ... , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of ... Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native who ... Hardy , “While sitting up in bed, I felt a pounding headache. It was ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 ... and Others The global anti-obesity drugs market ... first half of the forecast period and CAGR of 38.7% in ... to grow at a CAGR of 32.8% from 2016 to 2027. ... in 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
Breaking Medicine Technology: